339 related articles for article (PubMed ID: 12829671)
41. A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma.
Kong DS; Lee JI; Kim WS; Son MJ; Lim DH; Kim ST; Park K; Kim JH; Eoh W; Nam DH
Oncol Rep; 2006 Nov; 16(5):1117-21. PubMed ID: 17016602
[TBL] [Abstract][Full Text] [Related]
42. Rechallenge with temozolomide in patients with recurrent gliomas.
Wick A; Pascher C; Wick W; Jauch T; Weller M; Bogdahn U; Hau P
J Neurol; 2009 May; 256(5):734-41. PubMed ID: 19240962
[TBL] [Abstract][Full Text] [Related]
43. Chemotherapy for the treatment of oligodendroglial tumors.
Chinot O
Semin Oncol; 2001 Aug; 28(4 Suppl 13):13-8. PubMed ID: 11550134
[TBL] [Abstract][Full Text] [Related]
44. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy.
Glass J; Hochberg FH; Gruber ML; Louis DN; Smith D; Rattner B
J Neurosurg; 1992 May; 76(5):741-5. PubMed ID: 1564535
[TBL] [Abstract][Full Text] [Related]
45. A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.
Neyns B; Chaskis C; Joosens E; Menten J; D'Hondt L; Branle F; Sadones J; Michotte A
Cancer Invest; 2008; 26(3):269-77. PubMed ID: 18317968
[TBL] [Abstract][Full Text] [Related]
46. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Nicholson HS; Kretschmar CS; Krailo M; Bernstein M; Kadota R; Fort D; Friedman H; Harris MB; Tedeschi-Blok N; Mazewski C; Sato J; Reaman GH
Cancer; 2007 Oct; 110(7):1542-50. PubMed ID: 17705175
[TBL] [Abstract][Full Text] [Related]
47. Phase II trial of temozolomide plus concurrent whole-brain radiation followed by TNV regimen as adjuvant therapy for patients with newly diagnosed primary CNS lymphoma.
Wang Y; Liu B; Xu D; Zhao H; Zhu Y; Xu J; Tao R
Neurol India; 2013; 61(3):260-4. PubMed ID: 23860145
[TBL] [Abstract][Full Text] [Related]
48. Temozolomide in the treatment of recurrent malignant glioma.
Chang SM; Theodosopoulos P; Lamborn K; Malec M; Rabbitt J; Page M; Prados MD
Cancer; 2004 Feb; 100(3):605-11. PubMed ID: 14745879
[TBL] [Abstract][Full Text] [Related]
49. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
[TBL] [Abstract][Full Text] [Related]
50. Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.
Triebels VH; Taphoorn MJ; Brandes AA; Menten J; Frenay M; Tosoni A; Kros JM; Stege EB; Enting RH; Allgeier A; van Heuvel I; van den Bent MJ
Neurology; 2004 Sep; 63(5):904-6. PubMed ID: 15365146
[TBL] [Abstract][Full Text] [Related]
51. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas.
Soffietti R; Rudà R; Bradac GB; Schiffer D
Neurosurgery; 1998 Nov; 43(5):1066-73. PubMed ID: 9802850
[TBL] [Abstract][Full Text] [Related]
52. Temozolomide chemotherapy in patients with recurrent malignant gliomas.
Yang SH; Kim MK; Lee TK; Lee KS; Jeun SS; Park CK; Kang JK; Kim MC; Hong YK
J Korean Med Sci; 2006 Aug; 21(4):739-44. PubMed ID: 16891823
[TBL] [Abstract][Full Text] [Related]
53. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
[TBL] [Abstract][Full Text] [Related]
54. Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.
Thomas AA; Abrey LE; Terziev R; Raizer J; Martinez NL; Forsyth P; Paleologos N; Matasar M; Sauter CS; Moskowitz C; Nimer SD; DeAngelis LM; Kaley T; Grimm S; Louis DN; Cairncross JG; Panageas KS; Briggs S; Faivre G; Mohile NA; Mehta J; Jonsson P; Chakravarty D; Gao J; Schultz N; Brennan CW; Huse JT; Omuro A
Neuro Oncol; 2017 Oct; 19(10):1380-1390. PubMed ID: 28472509
[TBL] [Abstract][Full Text] [Related]
55. Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma.
Kong DS; Lee JI; Kim JH; Kim ST; Kim WS; Suh YL; Dong SM; Nam DH
Neuro Oncol; 2010 Mar; 12(3):289-96. PubMed ID: 20167817
[TBL] [Abstract][Full Text] [Related]
56. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
Jalali R; Basu A; Gupta T; Munshi A; Menon H; Sarin R; Goel A
Br J Neurosurg; 2007 Dec; 21(6):583-7. PubMed ID: 18071985
[TBL] [Abstract][Full Text] [Related]
57. A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme.
Aoki T; Mizutani T; Ishikawa M; Sugiyama K; Hashimoto N
Int J Clin Oncol; 2003 Oct; 8(5):301-4. PubMed ID: 14586755
[TBL] [Abstract][Full Text] [Related]
58. Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group.
Aoki T; Arakawa Y; Ueba T; Oda M; Nishida N; Akiyama Y; Tsukahara T; Iwasaki K; Mikuni N; Miyamoto S
Neurol Med Chir (Tokyo); 2017 Jan; 57(1):17-27. PubMed ID: 27725524
[TBL] [Abstract][Full Text] [Related]
59. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.
Osoba D; Brada M; Yung WK; Prados M
J Clin Oncol; 2000 Apr; 18(7):1481-91. PubMed ID: 10735896
[TBL] [Abstract][Full Text] [Related]
60. Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study.
Brandes AA; Basso U; Vastola F; Tosoni A; Pasetto LM; Jirillo A; Lonardi S; Paris MK; Koussis H; Monfardini S; Ermani M
Ann Oncol; 2003 Dec; 14(12):1727-31. PubMed ID: 14630676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
